Header Logo

Connection

Joan Walker to Aged

Back to Details
This is a "connection" page, showing publications Joan Walker has written about Aged.
Joan Walker
Connection Strength
2.271
Aged
  1. Two Cases of Malignant Proliferating Trichilemmal Tumor (MPTT) and Review of Literature. R I Med J (2013). 2022 Feb 01; 105(1):12-16.
    View in: PubMed
    Score: 0.095
  2. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.078
  3. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 01; 218(1):109.e1-109.e11.
    View in: PubMed
    Score: 0.070
  4. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017 05; 27(4):730-737.
    View in: PubMed
    Score: 0.068
  5. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.066
  6. Four Diseases, Two Associations, One Patient: A Case of Frontal Fibrosing Alopecia, Lichen Planus Pigmentosus, Acne Rosacea, and Morbihan Disease. Skinmed. 2016; 14(3):225-8.
    View in: PubMed
    Score: 0.064
  7. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7.
    View in: PubMed
    Score: 0.055
  8. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul; 130(1):12-8.
    View in: PubMed
    Score: 0.051
  9. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.049
  10. Tubal ligation frequency in Oklahoma women with cervical cancer. Gynecol Oncol. 2012 Nov; 127(2):278-82.
    View in: PubMed
    Score: 0.049
  11. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.047
  12. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.047
  13. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):529-33.
    View in: PubMed
    Score: 0.047
  14. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
    View in: PubMed
    Score: 0.045
  15. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
    View in: PubMed
    Score: 0.044
  16. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6.
    View in: PubMed
    Score: 0.040
  17. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):113-20.
    View in: PubMed
    Score: 0.038
  18. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008 Feb; 108(2):342-7.
    View in: PubMed
    Score: 0.035
  19. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2025 Aug 21; 393(8):774-785.
    View in: PubMed
    Score: 0.030
  20. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025 Apr; 195:122-133.
    View in: PubMed
    Score: 0.029
  21. Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: A retrospective cohort study. J Am Acad Dermatol. 2025 Jul; 93(1):157-164.
    View in: PubMed
    Score: 0.029
  22. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. Gynecol Oncol. 2025 Apr; 195:66-74.
    View in: PubMed
    Score: 0.029
  23. Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025 May; 92(5):1072-1079.
    View in: PubMed
    Score: 0.029
  24. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
    View in: PubMed
    Score: 0.028
  25. Merkel Cell Carcinoma. Dermatol Clin. 2023 Jan; 41(1):101-115.
    View in: PubMed
    Score: 0.025
  26. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.
    View in: PubMed
    Score: 0.023
  27. Rates of Opioid Prescriptions Obtained After Mohs Surgery: A Claims Database Analysis From 2009 to 2020. JAMA Dermatol. 2021 Nov 01; 157(11):1299-1305.
    View in: PubMed
    Score: 0.023
  28. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.
    View in: PubMed
    Score: 0.023
  29. Rate and Proportion of Malignant Skin Biopsies for Basal Cell and Squamous Cell Carcinoma on the Face and Ears After a Single Course of Topical 5-Fluorouracil: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial. Dermatol Surg. 2021 04 01; 47(4):541-543.
    View in: PubMed
    Score: 0.022
  30. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
    View in: PubMed
    Score: 0.022
  31. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
    View in: PubMed
    Score: 0.022
  32. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2021 01; 132(1):150-159.
    View in: PubMed
    Score: 0.022
  33. GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021 01; 160(1):244-251.
    View in: PubMed
    Score: 0.022
  34. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol. 2020 02; 156(2):467-474.
    View in: PubMed
    Score: 0.020
  35. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
    View in: PubMed
    Score: 0.020
  36. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.020
  37. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
    View in: PubMed
    Score: 0.020
  38. GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). Gynecol Oncol. 2019 12; 155(3):452-460.
    View in: PubMed
    Score: 0.020
  39. Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathol. 2018 11; 126(11):950-958.
    View in: PubMed
    Score: 0.019
  40. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
    View in: PubMed
    Score: 0.019
  41. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.019
  42. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
    View in: PubMed
    Score: 0.018
  43. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 07; 150(1):119-126.
    View in: PubMed
    Score: 0.018
  44. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.017
  45. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145.
    View in: PubMed
    Score: 0.017
  46. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.017
  47. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.017
  48. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.017
  49. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
    View in: PubMed
    Score: 0.017
  50. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.017
  51. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
    View in: PubMed
    Score: 0.016
  52. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clin Cancer Res. 2017 04 15; 23(8):1955-1966.
    View in: PubMed
    Score: 0.016
  53. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86.
    View in: PubMed
    Score: 0.016
  54. Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. J Low Genit Tract Dis. 2016 Apr; 20(2):154-61.
    View in: PubMed
    Score: 0.016
  55. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32.
    View in: PubMed
    Score: 0.016
  56. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.
    View in: PubMed
    Score: 0.015
  57. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. Gynecol Oncol. 2015 Jul; 138(1):101-8.
    View in: PubMed
    Score: 0.015
  58. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015 Jan 01; 33(1):83-9.
    View in: PubMed
    Score: 0.014
  59. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
    View in: PubMed
    Score: 0.014
  60. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
    View in: PubMed
    Score: 0.014
  61. Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. Cancer Cytopathol. 2014 Sep; 122(9):694-701.
    View in: PubMed
    Score: 0.014
  62. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.014
  63. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar; 132(3):585-92.
    View in: PubMed
    Score: 0.014
  64. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
    View in: PubMed
    Score: 0.013
  65. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.013
  66. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
    View in: PubMed
    Score: 0.013
  67. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4.
    View in: PubMed
    Score: 0.013
  68. Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study. Int J Gynecol Cancer. 2012 Nov; 22(9):1624-33.
    View in: PubMed
    Score: 0.012
  69. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer Causes Control. 2012 Dec; 23(12):2013-21.
    View in: PubMed
    Score: 0.012
  70. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50.
    View in: PubMed
    Score: 0.012
  71. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012 Aug 01; 18(15):4154-62.
    View in: PubMed
    Score: 0.012
  72. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):367-71.
    View in: PubMed
    Score: 0.012
  73. Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. J Clin Microbiol. 2012 May; 50(5):1564-70.
    View in: PubMed
    Score: 0.012
  74. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92.
    View in: PubMed
    Score: 0.012
  75. Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One. 2012; 7(1):e29051.
    View in: PubMed
    Score: 0.012
  76. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
    View in: PubMed
    Score: 0.012
  77. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
    View in: PubMed
    Score: 0.012
  78. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Feb; 120(2):224-8.
    View in: PubMed
    Score: 0.011
  79. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.011
  80. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
    View in: PubMed
    Score: 0.011
  81. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer. 2009 Nov 15; 125(10):2434-40.
    View in: PubMed
    Score: 0.010
  82. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Nov 10; 27(32):5337-42.
    View in: PubMed
    Score: 0.010
  83. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.010
  84. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol. 2009 Feb; 112(2):337-41.
    View in: PubMed
    Score: 0.009
  85. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan; 112(1):134-41.
    View in: PubMed
    Score: 0.009
  86. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008 Jun 01; 26(16):2674-82.
    View in: PubMed
    Score: 0.009
  87. Cervical dysplasia among women over 35 years of age. Am J Obstet Gynecol. 2008 Nov; 199(5):471.e1-5.
    View in: PubMed
    Score: 0.009
  88. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul; 110(1):76-82.
    View in: PubMed
    Score: 0.009
  89. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008 Mar; 108(3):584-90.
    View in: PubMed
    Score: 0.009
  90. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007 Jun 15; 109(12):2454-60.
    View in: PubMed
    Score: 0.009
  91. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 01; 25(4):437-43.
    View in: PubMed
    Score: 0.008
  92. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep; 102(3):432-9.
    View in: PubMed
    Score: 0.008
  93. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05; 354(1):34-43.
    View in: PubMed
    Score: 0.008
  94. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.008
  95. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.007
  96. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.007
  97. Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81.
    View in: PubMed
    Score: 0.007
  98. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003 Aug; 90(2):325-30.
    View in: PubMed
    Score: 0.007
  99. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. Gynecol Oncol. 2002 Mar; 84(3):426-30.
    View in: PubMed
    Score: 0.006
  100. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
    View in: PubMed
    Score: 0.006
  101. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8.
    View in: PubMed
    Score: 0.006
  102. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.006
  103. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.006
  104. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3.
    View in: PubMed
    Score: 0.005
  105. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 Jan 15; 73(2):370-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.